Phaseline

Targets › MS4A1

MS4A1 (B-lymphocyte antigen CD20): drug programs, companies and trials

28 programs from 22 companies in 535 trials: 296 Phase 2, 100 Phase 1, 92 Phase 3, 47 Phase 4; Oncology, Neurology, Immunology; next expected readout Nov 2026.

B-lymphocyte-specific membrane protein that plays a role in the regulation of cellular calcium influx necessary for the development, differentiation, and activation of B-lymphocytes. Functions as a store-operated calcium (SOC) channel component promoting calcium influx after activation by the B-cell receptor/BCR. (UniProt, P11836)

Open in Phaseline: the race on MS4A1, likelihood bands and readouts

Programs

CompanyDrugTargetsHighest phaseConditionsNext expected readout
University of California, San FranciscoIntravenous TXA
Interleukin-23 inhibitor
ADRB2, AGTR1, IL12B, IL23A, PDCD1, NR3C1, HTR2A, MAP2K1, MAP2K2, MS4A1, CHRM3, CHRM2, ADRB3, OPRM1, CYP19A1, CHRNB2, CHRNA4Phase 4Child Mortality; Relapsing Multiple Sclerosis; Menstrual Regulation; Secondhand Smoke …Dec 2026
NovartisOfatumumab
B-lymphocyte antigen CD20 binding agent
MS4A1Phase 4Multiple Sclerosis; Relapsing-Remitting Multiple Sclerosis; Relapsing Multiple Sclerosis; Relapsing Multiple Sclerosis (RMS) …Apr 2027
RocheOcrelizumab
B-lymphocyte antigen CD20 binding agent
MS4A1Phase 4Relapsing Multiple Sclerosis; Progressive Multiple Sclerosis (PMS); Multiple Sclerosis; Multiple Sclerosis, Primary Progressive …Sep 2027
RocheOcrelizumab (rHuPH20)
B-lymphocyte antigen CD20 binding agent
MS4A1Phase 4Multiple SclerosisFeb 2029
AbbVieObinutuzumab
B-lymphocyte antigen CD20 binding agent
MS4A1Phase 3Chronic Lymphocytic Leukemia; Chronic Lymphocytic Leukemia (CLL)Nov 2026
SandozOcrelizumab (CYB704)
B-lymphocyte antigen CD20 binding agent
MS4A1Phase 3Relapsing Multiple SclerosisNov 2026
TG TherapeuticsUblituximab
B-lymphocyte antigen CD20 binding agent
MS4A1Phase 3Relapsing Multiple Sclerosis; Relapsing Multiple Sclerosis (RMS); Multiple Sclerosis; Myasthenia Gravis …Jan 2027
RocheGlofitamab
B-lymphocyte antigen CD20 binding agent; T cell surface glycoprotein CD3 binding agent
MS4A1, CD3E, CD3G, CD3DPhase 3Lymphoma; Large B-Cell Lymphoma; Diffuse Large B-cell Lymphoma; Relapsed or Refractory Aggressive B-Cell Non-Hodgkins Lymphoma …Jan 2027
Biocaddivozilimab
anti-CD20 monoclonal antibody
MS4A1Phase 3Neuromyelitis Optica Spectrum Disorders; Systemic SclerodermaFeb 2027
CelltrionOcrelizumab (P53)
B-lymphocyte antigen CD20 binding agent
MS4A1Phase 3Relapsing-remitting Multiple SclerosisFeb 2027
Acerta PharmaRituximab
B-lymphocyte antigen CD20 binding agent
MS4A1Phase 3Diffuse Large B-Cell LymphomaFeb 2027
RocheMosunetuzumab
T cell surface glycoprotein CD3 binding agent; B-lymphocyte antigen CD20 binding agent
CD3E, CD3G, CD3D, MS4A1Phase 3Non-Hodgkin Lymphoma; Relapsed or Refractory Follicular Lymphoma; Lupus; B-cell Non-Hodgkin Lymphoma …Feb 2027
GenmabEpcoritamab
B-lymphocyte antigen CD20 binding agent; T cell surface glycoprotein CD3 binding agent
MS4A1, CD3E, CD3G, CD3DPhase 3Diffuse Large B-Cell Lymphoma; Diffuse Large B-cell Lymphoma; Follicular Lymphoma (FL); Non-Hodgkin Lymphoma …Mar 2027
AmgenABP 692
Anti-CD20 monoclonal antibody
MS4A1Phase 3Relapsing-remitting Multiple Sclerosis (RRMS)Apr 2027
Acerta PharmaObinutuzumab
B-lymphocyte antigen CD20 binding agent
MS4A1Phase 3Chronic Lymphocytic LeukemiaApr 2027
RocheObinutuzumab
B-lymphocyte antigen CD20 binding agent
MS4A1Phase 3Childhood Idiopathic Nephrotic Syndrome; Primary Membranous Nephropathy; Systemic Lupus Erythematosus; Lupus Nephritis …Dec 2027
Regeneron PharmaceuticalsOdronextamab
B-lymphocyte antigen CD20 binding agent; T cell surface glycoprotein CD3 binding agent
MS4A1, CD3E, CD3G, CD3DPhase 3Follicular Lymphoma (FL); Diffuse Large B-cell Lymphoma (DLBCL); B-Cell Non-Hodgkin Lymphoma (B-NHL); Relapsed/Refractory Follicular Lymphoma …Feb 2028
Bristol-Myers SquibbRituximab
B-lymphocyte antigen CD20 binding agent
MS4A1Phase 3Follicular LymphomaApr 2028
Shanghai Henlius BiotechRituximab (HLX01)
B-lymphocyte antigen CD20 binding agent
MS4A1Phase 2Membranous NephropathyJan 2027
BioRay PharmaceuticalRituximab
B-lymphocyte antigen CD20 binding agent
MS4A1Phase 2Primary Membranous NephropathyMar 2027
AstraZenecaRituximab
B-lymphocyte antigen CD20 binding agent
MS4A1Phase 2Mantle Cell Lymphoma (MCL); Diffuse Large B-Cell Lymphoma; Rheumatoid Arthritis (RA); ANCA Associated Vasculitis …Oct 2028
The Lymphoma Academic Research OrganisationCD20 Antibody
Anti-CD20 monoclonal antibody
MS4A1Phase 2Mantle Cell LymphomaMar 2030
PolTREGrituximab
B-lymphocyte antigen CD20 binding agent
MS4A1Phase 2Presymptomatic Diabetes Type 1 (Stage 1)Dec 2032
ByondisRituximab (BYON4228)
B-lymphocyte antigen CD20 binding agent
MS4A1, SIRPAPhase 1Lymphoma; Solid TumorDec 2026
ImmunityBioRituximab (CD19)
B-lymphocyte antigen CD20 binding agent
MS4A1Phase 1Non-Hodgkin Lymphoma Refractory/ RelapsedOct 2027
R-PharmOcrelizumab (RPH-035)
B-lymphocyte antigen CD20 binding agent
MS4A1Phase 1Multiple SclerosisNov 2027
Shanghai JMT-BioJMT601
anti-CD20 monoclonal antibody
MS4A1Phase 1B-cell Non Hodgkin Lymphoma–
BiocadRituximab
B-lymphocyte antigen CD20 binding agent
MS4A1Phase 1Systemic Lupus Erthematosus–

Conditions

Follicular Lymphoma (25) Mantle Cell Lymphoma (25) Chronic Lymphocytic Leukemia (25) Multiple Sclerosis (18) Lymphoma (15) Diffuse Large B-Cell Lymphoma (13) Marginal Zone Lymphoma (11) Large B-cell Lymphoma (9) Relapsing Multiple Sclerosis (8) Diffuse Large B Cell Lymphoma (8) Primary Central Nervous System Lymphoma (7) Recurrent Diffuse Large B-Cell Lymphoma (6)

Modalities

mixed (16), protein or peptide (4), antibody (4), small molecule (3)

Companies

Roche (5) Biocad (2) Acerta Pharma (2) Regeneron Pharmaceuticals (1) Sandoz (1) Celltrion (1) TG Therapeutics (1) Genmab (1) Novartis (1) AbbVie (1) AstraZeneca (1) Bristol-Myers Squibb (1) University of California, San Francisco (1) ImmunityBio (1) Shanghai Henlius Biotech (1) Byondis (1) The Lymphoma Academic Research Organisation (1) BioRay Pharmaceutical (1) Amgen (1) PolTREG (1)

Related targets

CD3E (4) CD3G (4) CD3D (4) ADRB2 (1) AGTR1 (1) IL12B (1) IL23A (1) PDCD1 (1) NR3C1 (1) HTR2A (1) MAP2K1 (1) MAP2K2 (1)

Programs group each company's trials by drug; targets and mechanisms come from Open Targets and ChEMBL via Open Targets; expected readouts are Phaseline's estimate from the registry's primary completion date. Facts from the registries only; the approval likelihood is in the app.